Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Shares Outstanding (Weighted Average) (2016 - 2025)

Enanta Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 14 years, with the latest figure at $28.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 35.36% year-over-year to $28.7 million; the TTM value through Dec 2025 reached $28.7 million, up 35.36%, while the annual FY2025 figure was $21336.0, 0.85% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $28.7 million in Q4 2025 per ENTA's latest filing, up from $21336.0 in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $28.7 million in Q4 2025 to a low of $20171.0 in Q3 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $16.0 million, with a median of $20.8 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Weighted Average): increased 0.71% in 2024, then skyrocketed 35.36% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $20.4 million in 2021, then rose by 2.1% to $20.8 million in 2022, then increased by 1.31% to $21.1 million in 2023, then grew by 0.71% to $21.2 million in 2024, then skyrocketed by 35.36% to $28.7 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Shares Outstanding (Weighted Average) are $28.7 million (Q4 2025), $21336.0 (Q3 2025), and $21.4 million (Q2 2025).